miragenews.com
Cure8 news brief
Why This Matters
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and potentially delay relapse.
If proven safe and effective in humans, the approach could offer a non-pharmacologic option to maintain remission.
Who Should Pay Attention
People with Crohn's disease (including adolescents and adults), caregivers and parents of pediatric patients, gastroenterologists and clinical researchers interested in diet- and microbiome-based therapies, and people considering clinical trial participation.
Study Snapshot
Story typeResearch news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
This article describes early-stage translational research and an ongoing clinical study rather than established new therapy. The intervention combines an already used dietary treatment (EEN) with screened donor fecal microbiome transfer in capsule form; the team is recruiting participants and manufacturing capsules at a university hospital.
The investigators state their main questions are safety, feasibility, and whether the microbiome can be durably reshaped after EEN to maintain remission. If you are considering trial participation, note this report does not provide results from the human study yet.
Clinical details, eligibility, and results will be available from the trial team and peer-reviewed publications when complete. For current care decisions, discuss with your gastroenterology team rather than changing treatment based on this news.
The original source links to the published Cell Host & Microbe paper describing the mechanistic work and to the EEN-RICH trial site for more information on participation.
Keep In Mind
The article reports on preclinical findings and the start of a clinical study (EEN-RICH). The human trial is ongoing and aims to assess safety, feasibility, and effect on relapse; no clinical outcomes from humans are reported here. FMT has established uses in other conditions but remains investigational for Crohn's disease; participation requires screening and oversight.
Read the original published study and trial registry for full methods and eligibility.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmiragenews.com
Indexed viaBing News
Source typeResearch news
PublishedFeb 11, 2025, 6:46 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
Study explores microbiome reboot to prolong effect of Crohn's disease therapy
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...
Targeted phages curb Crohn's-linked gut inflammation by disabling harmful E. coli traits
This study suggests a new, targeted way to reduce gut inflammation by disabling harmful E. coli behaviors linked to Crohn's disease without wiping out the microbiome.